These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 29544530)

  • 1. Economic evaluation of HIV pre-exposure prophylaxis strategies: protocol for a methodological systematic review and quantitative synthesis.
    Thavorn K; Kugathasan H; Tan DHS; Moqueet N; Baral SD; Skidmore B; MacFadden D; Simkin A; Mishra S
    Syst Rev; 2018 Mar; 7(1):47. PubMed ID: 29544530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
    Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
    Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.
    Kessler J; Myers JE; Nucifora KA; Mensah N; Toohey C; Khademi A; Cutler B; Braithwaite S
    AIDS; 2014 Nov; 28(18):2683-91. PubMed ID: 25493594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward.
    Case KK; Gomez GB; Hallett TB
    J Int AIDS Soc; 2019 Sep; 22(9):e25390. PubMed ID: 31538407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
    van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the study topics and characteristics of HIV pre-exposure prophylaxis research literature: a protocol for a scoping review.
    Kamitani E; Johnson AH; Wichser M; Mizuno Y; DeLuca JB; Higa DH
    BMJ Open; 2019 May; 9(5):e024212. PubMed ID: 31129574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
    Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
    Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
    Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
    PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public sector.
    Peebles K; Mugwanya KK; Irungu E; Odoyo J; Wamoni E; Morton JF; Ngure K; Bukusi EA; Mugo NR; Masyuko S; Mukui I; Baeten JM; Barnabas RV;
    BMC Health Serv Res; 2021 Aug; 21(1):823. PubMed ID: 34399736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review.
    Bozzani FM; Terris-Prestholt F; Quaife M; Gafos M; Indravudh PP; Giddings R; Medley GF; Malhotra S; Torres-Rueda S
    Pharmacoeconomics; 2023 May; 41(5):467-480. PubMed ID: 36529838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
    Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S
    Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive.
    Letchumanan M; Coyte PC; Loutfy M
    Antivir Ther; 2015; 20(6):613-21. PubMed ID: 25849113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
    Alistar SS; Owens DK; Brandeau ML
    PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer.
    Sharma S; Carey N; McConnell D; Lowery M; O'Sullivan J; McCullagh L;
    Pharmacoeconomics; 2024 Oct; 42(10):1091-1110. PubMed ID: 39060831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review.
    Vanhamel J; Rotsaert A; Reyniers T; Nöstlinger C; Laga M; Van Landeghem E; Vuylsteke B
    BMC Health Serv Res; 2020 Jul; 20(1):704. PubMed ID: 32736626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.